PURPOSE: To provide in absolute terms a quantification of regionalization of care from low- to high-volume hospitals in patients treated with nephrectomy for non-metastatic renal cell carcinoma. METHODS: Relying on the Nationwide Inpatient Sample, 48,172 patients with non-metastatic renal cell carcinoma undergoing nephrectomy were identified. All analyses focused on five specific endpoints: intraoperative complications, postoperative complications, blood transfusions, prolonged hospitalization, and in-hospital mortality. First, multivariable logistic regression models for prediction of the aforementioned endpoints were fitted among high-volume hospitals treated patients. Second, obtained coefficients from such models were applied onto low-volume hospitals treated individuals. Potentially avoidable events were computed through differences between observed and predicted adverse events. The number needed to treat was generated. RESULTS: Low-volume hospitals treated individuals were between 11 and 28 % more likely to succumb to an adverse outcome (all P < 0.001). Differences between observed and predicted adverse outcome rates were all in favor of high-volume hospitals, except for in-hospital mortality. Potentially avoidable intraoperative complications, postoperative complications, blood transfusions, prolonged hospitalization, and in-hospital mortality rates were 1.4, 5.6, 7.6, 24.0, and 0.7 %, respectively. Thus, for every 71, 18, 13, 4, and 143 nephrectomies that are redirected to high-volume hospitals, 1 intraoperative complication, postoperative complication, blood transfusion, prolonged hospitalization, and in-hospital mortality could be potentially avoided. CONCLUSIONS: Regionalization from low- to high-volume hospitals for patients undergoing a nephrectomy is associated with important benefits, for both the payer and patient's perspectives.
PURPOSE: To provide in absolute terms a quantification of regionalization of care from low- to high-volume hospitals in patients treated with nephrectomy for non-metastatic renal cell carcinoma. METHODS: Relying on the Nationwide Inpatient Sample, 48,172 patients with non-metastatic renal cell carcinoma undergoing nephrectomy were identified. All analyses focused on five specific endpoints: intraoperative complications, postoperative complications, blood transfusions, prolonged hospitalization, and in-hospital mortality. First, multivariable logistic regression models for prediction of the aforementioned endpoints were fitted among high-volume hospitals treated patients. Second, obtained coefficients from such models were applied onto low-volume hospitals treated individuals. Potentially avoidable events were computed through differences between observed and predicted adverse events. The number needed to treat was generated. RESULTS: Low-volume hospitals treated individuals were between 11 and 28 % more likely to succumb to an adverse outcome (all P < 0.001). Differences between observed and predicted adverse outcome rates were all in favor of high-volume hospitals, except for in-hospital mortality. Potentially avoidable intraoperative complications, postoperative complications, blood transfusions, prolonged hospitalization, and in-hospital mortality rates were 1.4, 5.6, 7.6, 24.0, and 0.7 %, respectively. Thus, for every 71, 18, 13, 4, and 143 nephrectomies that are redirected to high-volume hospitals, 1 intraoperative complication, postoperative complication, blood transfusion, prolonged hospitalization, and in-hospital mortality could be potentially avoided. CONCLUSIONS: Regionalization from low- to high-volume hospitals for patients undergoing a nephrectomy is associated with important benefits, for both the payer and patient's perspectives.
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Hugh R Waters; Roy Korn; Elizabeth Colantuoni; Sean M Berenholtz; Christine A Goeschel; Dale M Needham; Julius C Pham; Allison Lipitz-Snyderman; Sam R Watson; Patricia Posa; Peter J Pronovost Journal: Am J Med Qual Date: 2011 Sep-Oct Impact factor: 1.852
Authors: Lars Budäus; Firas Abdollah; Maxine Sun; Monica Morgan; Rupinder Johal; Rodolphe Thuret; Kevin C Zorn; Hendrik Isbarn; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Markus Graefen; Pierre I Karakiewicz Journal: J Urol Date: 2010-10-16 Impact factor: 7.450
Authors: Maxine Sun; Marco Bianchi; Quoc-Dien Trinh; Firas Abdollah; Jan Schmitges; Claudio Jeldres; Shahrokh F Shariat; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: J Urol Date: 2011-12-15 Impact factor: 7.450
Authors: Vincent Cloutier; Umberto Capitanio; Laurent Zini; Paul Perrotte; Claudio Jeldres; Shahrokh F Shariat; Philippe Arjane; Jean-Jacques Patard; Francesco Montorsi; Pierre I Karakiewicz Journal: Eur Urol Date: 2008-11-25 Impact factor: 20.096
Authors: Shreyas S Joshi; Elizabeth A Handorf; Matthew Zibelman; Elizabeth R Plimack; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone; Daniel M Geynisman Journal: Eur Urol Date: 2018-06-05 Impact factor: 20.096
Authors: Brian T Kadow; Shreyas S Joshi; Alexander Kutikov; Elizabeth Handorf; Marc C Smaldone; Robert G Uzzo; Daniel M Geynisman Journal: Ann Transl Med Date: 2019-12
Authors: Joshua Sterling; Zorimar Rivera-Núñez; Hiren V Patel; Nicholas J Farber; Sinae Kim; Kushan D Radadia; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer Journal: Clin Genitourin Cancer Date: 2020-03-20 Impact factor: 2.872
Authors: Ray C J Hsu; Theodosia Salika; Jonathan Maw; Georgios Lyratzopoulos; Vincent J Gnanapragasam; James N Armitage Journal: BMJ Open Date: 2017-09-05 Impact factor: 2.692
Authors: Ray C J Hsu; Matthew Barclay; Molly A Loughran; Georgios Lyratzopoulos; Vincent J Gnanapragasam; James N Armitage Journal: BJU Int Date: 2019-07-15 Impact factor: 5.588